Sign in
CompletedNo phase

GLP-1 RA Cessation and Gastric Ultrasound Findings

Key facts

Who runs it
Wonkwang University Hospital
Where
South Korea1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
186 people enrolled
Started
1 Jul 2026
Ended
4 Aug 2026
Type of study
Observational, 3 groups
Treatments tested
  • GLP-1 RA Cessation Interval
Record updated
5 August 2026

Who can take part

Age
19 years to 65 years
Sex
Women and men
Show the full registry criteria (8)Hide the full registry criteria

Who can take part

  • Adults aged 18 years or older
  • Patients receiving a glucagon-like peptide-1 receptor agonist
  • Patients scheduled for elective non-cardiac surgery requiring general anesthesia
  • Patients able to provide written informed consent

Who cannot take part

  • Emergency surgery
  • History of prior gastric surgery
  • Known gastroparesis or severe gastroesophageal reflux disease
  • Declined or unable to provide written informed consent

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This prospective observational study will evaluate the association between the time interval since the last dose of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and residual gastric contents before elective surgery. Adult patients receiving GLP-1 RAs and scheduled for elective non-cardiac surgery under general anesthesia will undergo preoperative point-of-care gastric ultrasound. The study will assess whether longer GLP-1 RA cessation intervals are associated with lower ultrasound-estimated gastric volume and a lower frequency of high-risk gastric contents. Body mass index will also be evaluated as a potential modifier of this association.

The 3 groups in the trial

  • Last GLP-1 RA Dose 3 Days or Less

    Participants receiving glucagon-like peptide-1 receptor agonists whose last dose was taken 3 days or less before elective surgery. No intervention was assigned by the study protocol; GLP-1 RA management followed usual clinical care. Participants underwent preoperative point-of-care gastric ultrasound to assess residual gastric contents.

    Treatment: GLP-1 RA Cessation Interval

  • Last GLP-1 RA Dose 4 to 7 Days

    Participants receiving glucagon-like peptide-1 receptor agonists whose last dose was taken 4 to 7 days before elective surgery. No intervention was assigned by the study protocol; GLP-1 RA management followed usual clinical care. Participants underwent preoperative point-of-care gastric ultrasound to assess residual gastric contents.

    Treatment: GLP-1 RA Cessation Interval

  • Last GLP-1 RA Dose 8 Days or More

    Participants receiving glucagon-like peptide-1 receptor agonists whose last dose was taken 8 days or more before elective surgery. No intervention was assigned by the study protocol; GLP-1 RA management followed usual clinical care. Participants underwent preoperative point-of-care gastric ultrasound to assess residual gastric contents.

    Treatment: GLP-1 RA Cessation Interval

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Time-dependent Association Between Cessation of Glucagon-like Peptide-1 Receptor Agonists and Residual Gastric Contents Assessed by Point-of-care Gastric Ultrasound: a Prospective Observational Study
Record updated
5 August 2026